Christophe Weber, Takeda CEO (Shoko Takayasu/Bloomberg via Getty Images)
September 21, 2022 07:40 AM EDT
R&D

Take­da punts dis­ap­point­ing late-stage Mil­len­ni­um drug for $7M in cash

Amber Tong

Take­da has man­aged to of­fload an ex­per­i­men­tal can­cer drug that’s been sit­ting on the shelf — in ex­change for $7 mil­lion in cash plus mile­stones. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times